trending Market Intelligence /marketintelligence/en/news-insights/trending/ypTLvcfg1o6_1bWZcbbeHg2 content esgSubNav
In This List

Neptune, Enzymotec end all patent litigation

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Neptune, Enzymotec end all patent litigation

Neptune Technologies & Bioressources Inc. and Enzymotec Ltd., along with its unit Enzymotec USA Inc., reached a broad patent cross-licensing agreement, ending all outstanding litigation between the companies.

Under the settlement and licensing agreement, Israel-based Enzymotec will make a one-time payment of about US$1.6 million to Canada-based Neptune. Further, Neptune will extend Enzymotec's worldwide and royalty-free license to its krill-related patents, while Enzymotec will grant Neptune a worldwide and royalty-free license to its krill-related patents.

Ending the legal challenges will allow the parties to promote joint efforts to respect each other's intellectual property and concentrate on the development of the omega-3 krill oil market, according to a news release.